Search Results
Your search for A matches 33047 pages
Showing 3901 - 3950Addressing Racial Disparities in Cancer Pain Management: A Potential Role for Music Therapy
Guest Editor’s Note: Despite its high prevalence, cancer pain remains undertreated. Racial disparities present further challenges to assessing and managing pain. Music therapy, a nonpharmacologic intervention, has been documented to be effective in controlling cancer pain. In this article, Kevin T. ...
Interruption of Endocrine Therapy to Attempt Pregnancy in Women With Hormone Receptor–Positive Early Breast Cancer
In a study reported in The New England Journal of Medicine, Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, and colleagues found that temporary interruption of adjuvant endocrine therapy to attempt pregnancy was not associated with increased short-term risk of breast cancer events among ...
Expert Point of View: Loren Laine, MD
Abstract discussant, Loren Laine, MD, Digestive Disease Week Council Chair and Professor of Medicine, Digestive Diseases, at Yale School of Medicine, acknowledged the clear link between obesity and various types of cancer and noted it logically follows that weight loss may help to reduce this risk. ...
Can Bariatric Surgery Decrease the Risk of Obesity-Related Cancers?
A new study presented at Digestive Disease Week 2023 has shown that just 4% of patients with obesity who underwent bariatric surgery developed obesity-associated cancer in a 10-year follow-up, compared with 8.9% among those who did not have a weight-loss procedure.1 These findings indicate that the ...
ASCO Member Testifies Before Congress to Urge Significant Increase in Federal Cancer Research Funding
The Association for Clinical Oncology (ASCO) continues to urge Congress to robustly fund the National Institutes of Health (NIH), National Cancer Institute (NCI), and the Advanced Research Projects Agency for Health (ARPA-H) in Fiscal Year 2024. In testimony submitted to the Senate Committee on...
ASCO Updates Guideline for Management of Anxiety and Depression in Adult Cancer Survivors
Cancer takes a significant psychological toll on affected individuals. Cancer survivors have a significantly elevated risk of developing a mental health disorder compared with the general population, yet their psychological symptoms are often underrecognized and undertreated. To help equip...
Expert Point of View: Devraj Basu, MD, PhD, FACS
Devraj Basu, MD, PhD, FACS, of the Perelman School of Medicine, University of Pennsylvania, an expert in human papillomavirus (HPV)-related oropharyngeal cancer, commented on this study: “This abstract shows lack of awareness of multiple types of HPV-associated cancer and a reduced awareness of...
Better Awareness of HPV-Associated Cancers Is Still Needed in the United States, Study Finds
Awareness of the link between the human papillomavirus (HPV) and HPV-associated cervical cancers has declined over time, and awareness of other HPV-associated cancers, such as oral, penile, and anal, remains low, according to a cross-sectional study of the U.S. population presented at the 2023...
Expert Point of View: Matteo Lambertini, MD, PhD
Invited discussant of these two trials, Matteo Lambertini, MD, PhD, Associate Professor at the University of Genova–IRCCS Policlinico San Martino Hospital Genoa, Italy, emphasized the importance of longer follow-up periods for both these clinical trials and the need to wait for the additional...
Two Studies of Atezolizumab-Based Regimens in Early-Stage, Triple-Negative and HER2-Positive Breast Cancers
Immunotherapy regimens involving the PD-L1 monoclonal antibody atezolizumab have demonstrated promising results in patients with early-stage, triple-negative breast cancer and HER2-positive breast cancer, according to a pair of studies presented at the European Society for Medical Oncology (ESMO)...
Rami Manochakian, MD, on NSCLC: Commentary on the ADAURA Trial of Osimertinib
Rami Manochakian, MD, of Mayo Clinic Florida, offers his perspective on the new phase III findings on osimertinib, a third-generation, central nervous system EGFR tyrosine kinase inhibitor, which demonstrated an unprecedented overall survival benefit for patients with EGFR-mutated, stage IB–IIIA...
Expert Point of View: Tina Cascone, MD, PhD
Discussant of the Neotorch study abstract, Tina Cascone, MD, PhD, of the Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, commended the authors for completing the initial analysis of the phase III randomized Neotorch trial, which...
Toripalimab Plus Chemotherapy Improves Event-Free Survival in Resectable Stage III NSCLC
Findings from a phase III, randomized trial highlight the benefit derived from perioperative immunotherapy in patients with early-stage resectable non–small cell lung cancer (NSCLC), according to data presented during the ASCO Plenary Series: April 2023 Session.1 Interim analysis of the Neotorch...
Pembrolizumab Added to Chemotherapy Improves Survival in Advanced Cervical Cancer Regardless of PD-L1 Expression
The addition of pembrolizumab to chemotherapy with or without bevacizumab led to improved overall survival and progression-free survival in women with persistent, recurrent, or metastatic cervical cancer in the final protocol-specified overall survival analysis of the KEYNOTE-826 trial presented at ...
Rethinking Prior Authorization
Prior authorization of medical procedures, services, and medications has been a standard requirement of health-care providers for decades. Rising health-care costs, specifically the escalating prices of cancer drug therapies, have led to a new focus by payers, providers, and policymakers on prior...
Endocrine Therapy Switch With or Without Ribociclib After Disease Progression on Endocrine Therapy and CDK4/6 Inhibition for Metastatic Breast Cancer
In the phase II MAINTAIN trial reported in the Journal of Clinical Oncology, Kevin Kalinsky, MD, MS, and colleagues found that a switch in endocrine therapy plus continued CDK4/6 inhibitor treatment with ribociclib was associated with improved progression-free survival in patients with hormone...
5α-Reductase Inhibitor Use and Progression of Bladder Cancer in South Korean Males
In a Korean cohort study reported in JAMA Network Open, An et al found that men with prescriptions for 5α-reductase inhibitors prior to diagnosis of urothelial bladder cancer had better outcomes than those with no prior prescriptions. Study Details The study analyzed patient claims data from the...
Reducing Air Pollution Globally May Contribute to Healthier Lifestyles and Lower Cancer Risks
The Union for International Cancer Control (UICC) has called for global action to improve public health and prevent millions of deaths from cancer and other noncommunicable diseases by drastically reducing air pollution in light of World Environment Day on June 5, 2023. "Creating cleaner and...
Cancer Survivors Who Quit Smoking May Have 36% Lower Cardiovascular Risk Than Those Who Continue Smoking
Patients who continue smoking after a cancer diagnosis may have almost a twofold risk of experiencing a heart attack, stroke, or death as a result of cardiovascular disease compared with nonsmokers, according to a new study published by Lee et al in the European Heart Journal. Background According...
NCCN Addresses Ongoing Chemotherapy Shortages as New Survey Suggests More than 90% of Cancer Centers May Be Impacted
Results of a new survey from the National Comprehensive Cancer Network (NCCN) have shed light on the widespread impact of the current carboplatin and cisplatin shortages. In a separate statement, the NCCN called on the whole oncology community to work together on solutions. Background Carboplatin...
Involving All of Society to End Cancer as We Know It
This has been a year of firsts and seconds for Monica M. Bertagnolli, MD, FACS, FASCO. This past October, Dr. Bertagnolli became the 16th Director of the National Cancer Institute (NCI), the first woman and the first clinical trials cooperative group chair to hold that position. Then, 2 months...
Second-Generation Antiandrogens and Cognitive and Functional Toxicity in Patients With Prostate Cancer
In a systematic review and meta-analysis reported in JAMA Oncology, Nowakowska et al found that use of second-generation antiandrogens for the treatment of prostate cancer was associated with increased risk of cognitive toxicity, fatigue, and falls in patients. Study Details The analysis included...
Expert Point of View: Mikkael A. Sekeres, MD
Mikkael A. Sekeres, MD, Professor of Medicine and Chief of the Division of Hematology, Sylvester Cancer Center, University of Miami, said the COMMANDS trial delivered promising results for the treatment of lower-risk myelodysplastic syndrome (MDS). “Without question, the COMMANDS study met its...
COMMANDS Trial: First-Line Luspatercept Boosts Chance of Transfusion Independence in Lower-Risk MDS
In the global phase III COMMANDS trial of patients with low-risk transfusion-dependent myelodysplastic syndrome (MDS), with or without ring sideroblasts, treatment with luspatercept essentially doubled the likelihood of achieving transfusion independence and an increase in hemoglobin level,...
Cathy Eng, MD, and Thejus Jayakrishnan, MD, on Colorectal Cancer: Metabolomic Differences in Young-Onset vs Average-Onset Disease
Cathy Eng, MD, of Vanderbilt-Ingram Cancer Center, and Thejus Jayakrishnan, MD, of the Cleveland Clinic Taussig Cancer Institute, discuss significant differences in the citrate cycle, a core pathway of cellular metabolism associated with colorectal cancer. Metabolomic differences impacted by...
Jennifer A. Woyach, MD, on New Findings on CLL, COVID-19, and Treatment With Obinutuzumab Plus Venetoclax
Jennifer A. Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses results of a phase III study showing that progression-free survival with ibrutinib plus obinutuzumab plus venetoclax is not superior to ibrutinib plus obinutuzumab for treatment-naive older patients with...
Anthracycline-Related Cardiomyopathy and HP Gene Expression in Childhood Cancer Survivors
In a study reported in JACC: CardioOncology, Singh et al found that haptoglobin (HP) gene expression was associated with risk of anthracycline-related cardiomyopathy in childhood cancer survivors. Study Details In the study, messenger RNA sequencing was performed on total RNA from the peripheral...
Allostatic Load and Mortality in Patients With Breast Cancer
In a study reported in JAMA Network Open, Samilia Obeng-Gyasi, MD, MPH, and colleagues found that allostatic load—defined as “a cumulative measure of physiologic damage secondary to cognitive-emotional responses and perceptions to socioenvironmental stressors (ie, low socioeconomic status)”—was...
Microdoses of Incisional Antibiotics and Surgical Site Infections in Surgery for Skin Cancer
In a single-institution study conducted in New Zealand reported in JAMA Surgery, Goh et al found that microdoses of incisional antibiotics may reduce the risk of surgical site infections during surgery for skin cancer, as well as reduce the risk of infections requiring postoperative systemic...
Black and Hispanic Cancer Survivors May Have Highest Risk of Death From Subsequent Primary Cancers and Cardiovascular Disease
Black and Hispanic cancer survivors with subsequent primary malignancies may have a higher risk of mortality compared with White patients, according to new findings presented by Sung et al at the 2023 ASCO Annual Meeting (Abstract 12093). The new research demonstrated that Black patients with...
Cancer Survivors With Transportation Barriers to Care May Also Experience Financial Hardship, Food Insecurity, and Delays in Timely Care
Investigators have found that many U.S. cancer survivors with transportation barriers to care also reported struggling financially and experiencing additional barriers to timely care, according to new findings presented by Jiang et al at the 2023 ASCO Annual Meeting (Abstract 6534). Study Methods...
ASCO Issues Clinical Guidance for Treating Gastrointestinal Cancers Amid Acute Drug Shortages
ASCO has issued new clinical guidance for treating patients with gastrointestinal cancers amid a nationwide shortage of carboplatin and cisplatin. The two chemotherapy agents, in extremely short supply, are essential to treating an array of gastrointestinal cancers—such as esophageal cancer,...
Radiation Treatment May Not Be Necessary After Chemoimmunotherapy for Primary Mediastinal B-Cell Lymphoma
Results from the largest prospective study of patients with primary mediastinal B-cell lymphoma (PMBCL) showed that radiation therapy may be omitted in patients who have a complete metabolic response after chemoimmunotherapy. The IELSG37 international study found that these patients may be spared...
Stopping Immunotherapy After 2 Years vs Continuing Treatment May Yield Similar Survival Outcomes in Patients With Advanced NSCLC
Patients with advanced non–small cell lung cancer (NSCLC) may be able to stop receiving immunotherapy at 2 years as long as their cancer hasn’t progressed, according to new findings presented by Sun et al at the 2023 ASCO Annual Meeting (Abstract 9101) and simultaneously published in JAMA Oncology. ...
Race and Ethnicity May Affect 21-Gene Recurrence Score in Patients With Estrogen Receptor–Positive Breast Cancer
Investigators have found that race and ethnicity may affect the 21-gene recurrence score in patients with early-stage, estrogen receptor–positive breast cancer, according to new findings presented by Gill et al at the 2023 ASCO Annual Meeting (Abstract 511). Background The 21-gene recurrence...
Exercise May Strengthen Immune System in Patients With Multiple Myeloma
Researchers have found that exercise may be effective at strengthening the immune system in patients with multiple myeloma, providing them with a nonpharmaceutical method of managing the disease, according to new findings presented by Joseph et al at the 2023 ASCO Annual Meeting (Abstract 8060)....
Axicabtagene Ciloleucel Improves Overall Survival in Patients With Relapsed or Refractory Large B-Cell Lymphoma
Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel when compared to the current standard-of-care chemoimmunotherapy, according to results of the...
Erdafitinib Achieves Responses Across Multiple Cancer Types With FGFR Alterations
Three clinical trials demonstrated positive results from the targeted therapy erdafitinib for patients with multiple tumor types harboring FGFR alterations. The data were presented at the 2023 ASCO Annual Meeting. Erdafitinib is an oral medication that blocks the activity of FGFR signaling...
Allison Betof Warner, MD, PhD, and Zeynep Eroglu, MD, on Metastatic Melanoma: New Data on Dabrafenib, Trametinib, and Navitoclax
Allison Betof Warner, MD, PhD, of Stanford University Medical Center, and Zeynep Eroglu, MD, of H. Lee Moffitt Cancer Center and Research Institute, discusses phase II findings showing that in patients with BRAF-mutant metastatic melanoma, dabrafenib plus trametinib and navitoclax (DTN) was...
Alicia K. Morgans, MD, MPH, and Praful Ravi, MRCP, MBBChir, on Localized Prostate Cancer: Prognostic Impact of PSA Nadir
Alicia K. Morgans, MD, MPH, and Praful Ravi, MRCP, MBBChir, both of Dana-Farber Cancer Institute, discuss an individual patient-data analysis of randomized trials from the ICECAP collaborative. A PSA nadir of ≥ 0.1 ng/mL within 6 months after radiotherapy completion was prognostic for prostate...
Arlene O. Siefker-Radtke, MD, on Metastatic Urothelial Carcinoma: New Data on Erdafitinib vs Chemotherapy From the THOR Study
Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings showing that for patients with advanced or metastatic urothelial carcinoma and FGFR alteration who already had been treated with a PD-(L)1 inhibitor, erdafitinib significantly improved...
Sarah K. Tasian, MD, on Hematologic Malignancies in Children: Expert Commentary
Sarah K. Tasian, MD, of Children’s Hospital of Philadelphia, summarizes three studies presented at ASCO: genomic determinants of outcome in acute lymphoblastic leukemia (ALL), a phase III trial of inotuzumab ozogamicin for high-risk B-cell ALL, and preliminary results from the first-in-child phase...
Jason J. Luke, MD, on Melanoma Adjuvant Therapy: Final Analysis of KEYNOTE-716
Jason J. Luke, MD, of the University of Pittsburgh Medical Center Hillman Cancer Center, discusses adjuvant pembrolizumab, which, in previous results, improved distant metastasis– and recurrence-free survival in patients with resected stage IIB or IIC melanoma vs placebo. After a median follow-up...
Narjust Florez, MD, and Heather A. Wakelee, MD, on Early-Stage NSCLC: Phase III Findings From KEYNOTE-671 on Pembrolizumab and Platinum-Based Chemotherapy
Narjust Florez, MD, of Dana-Farber Cancer Institute, and Heather A. Wakelee, MD, of Stanford University, Stanford Cancer Institute, discuss new data supporting neoadjuvant pembrolizumab plus chemotherapy followed by surgery and adjuvant pembrolizumab as a promising new treatment option for patients ...
Lisa A. Carey, MD, and Javier Cortes, MD, PhD, on HER2-Positive Early Breast Cancer: Chemotherapy De-escalation Under Study in PHERGain Trial
Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Javier Cortes, MD, PhD, of the International Breast Cancer Center and Universidad Europea de Madrid, discuss phase II findings showing that one in three patients with HER2-positive early breast cancer may safely omit...
Lisa A. Carey, MD, and Dennis J. Slamon, MD, PhD, on Early Breast Cancer: Findings From the NATALEE Trial on Ribociclib Plus Endocrine Therapy
Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Dennis J. Slamon, MD, PhD, of the University of California, Los Angeles, discuss phase III study findings on ribociclib plus endocrine therapy as adjuvant treatment in patients with hormone receptor–positive, HER2-negative...
Nirav N. Shah, MD, on Mantle Cell Lymphoma: Follow-up Data on Pirtobrutinib in Pretreated Disease
Nirav N. Shah, MD, of the Medical College of Wisconsin, discusses the efficacy and safety of pirtobrutinib, a highly selective, noncovalent BTK inhibitor, studied for more than 3 years in the BRUIN trial. The results showed that the use of pirtobrutinib continues to have durable efficacy and a...
Nirav N. Shah, MD, on Mantle Cell Lymphoma: Follow-up Data on Pirtobrutinib in Pretreated Disease
Nirav N. Shah, MD, of the Medical College of Wisconsin, discusses the efficacy and safety of pirtobrutinib, a highly selective, noncovalent BTK inhibitor, studied for more than 3 years in the BRUIN trial. The results showed that the use of pirtobrutinib continues to have durable efficacy and a...
Nirav N. Shah, MD, on DLBCL: New Data on Split-Dose R-CHOP for Older Patients
Nirav N. Shah, MD, of the Medical College of Wisconsin, discusses phase II results showing that split-dose R-CHOP offers older patients with diffuse large B-cell lymphoma (DLBCL) an equivalent dose intensity as R-CHOP-21 through a fractionated dosing schedule, improving tolerability. At the end of...
Funda Meric-Bernstam, MD, on HER2-Expressing Solid Tumors: Efficacy and Safety of Trastuzumab Deruxtecan
Funda Meric-Bernstam, MD, of The University of Texas MD Anderson Cancer Center, discusses interim results from the DESTINY-PanTumor02 trial, the first tumor-agnostic global study of fam-trastuzumab deruxtecan-nxki (T-DXd) in a broad range of HER2-expressing solid tumors. This agent showed an...
